317 related articles for article (PubMed ID: 10899827)
1. Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
[TBL] [Abstract][Full Text] [Related]
2. Analysis of lenti- and trans-lentiviral vector genetic recombination.
Wu X; Wakefield JK; Liu H; Kappes JC
Dev Biol (Basel); 2001; 106():237-48; discussion 249, 253-63. PubMed ID: 11761237
[TBL] [Abstract][Full Text] [Related]
3. Safety considerations in vector development.
Kappes JC; Wu X
Somat Cell Mol Genet; 2001 Nov; 26(1-6):147-58. PubMed ID: 12465466
[TBL] [Abstract][Full Text] [Related]
4. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
5. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
[TBL] [Abstract][Full Text] [Related]
6. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors.
Haas DL; Case SS; Crooks GM; Kohn DB
Mol Ther; 2000 Jul; 2(1):71-80. PubMed ID: 10899830
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
8. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells.
Choi JK; Hoang N; Vilardi AM; Conrad P; Emerson SG; Gewirtz AM
Stem Cells; 2001; 19(3):236-46. PubMed ID: 11359949
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
10. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
Lu X; Humeau L; Slepushkin V; Binder G; Yu Q; Slepushkina T; Chen Z; Merling R; Davis B; Chang YN; Dropulic B
J Gene Med; 2004 Sep; 6(9):963-73. PubMed ID: 15352069
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
12. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
13. Novel bovine lentiviral vectors based on Jembrana disease virus.
Metharom P; Takyar S; Xia HH; Ellem KA; Macmillan J; Shepherd RW; Wilcox GE; Wei MQ
J Gene Med; 2000; 2(3):176-85. PubMed ID: 10894263
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr.
Pang S; Kang MK; Kung S; Yu D; Lee A; Poon B; Chen IS; Lindemann B; Park NH
Clin Cancer Res; 2001 Nov; 7(11):3567-73. PubMed ID: 11705878
[TBL] [Abstract][Full Text] [Related]
15. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
Sparacio S; Pfeiffer T; Schaal H; Bosch V
Mol Ther; 2001 Apr; 3(4):602-12. PubMed ID: 11319923
[TBL] [Abstract][Full Text] [Related]
16. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
19. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.
Gao Z; Golob J; Tanavde VM; Civin CI; Hawley RG; Cheng L
Stem Cells; 2001; 19(3):247-59. PubMed ID: 11359950
[TBL] [Abstract][Full Text] [Related]
20. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
